Professional Title & Qualifications:
-
Chief Physician
-
Professor & Doctoral Supervisor
-
President of Fudan University Shanghai Cancer Center
-
Director of Pancreatic Cancer Institute, Fudan University
-
FACS (Fellow of the American College of Surgeons)
Specialization:
Hospital & Department：
Fudan University Shanghai Cancer Center – Department of Pancreatic Surgery
Dr. Xianjun Yu - Pancreatic Surgery Specialist
Personal Biography
Dr. Xianjun Yu is a distinguished Chief Physician, Professor, and Doctoral Supervisor. He currently serves as the President of Fudan University Shanghai Cancer Center (FUSCC) and the Director of the Department of Pancreatic Surgery. He also holds the position of Director at the Pancreatic Cancer Institute of Fudan University and the Shanghai Pancreatic Cancer Institute.
Dr. Yu received his M.D. and Ph.D. from Fudan University. He further honed his expertise through postdoctoral research and clinical training at the prestigious Baylor College of Medicine and MD Anderson Cancer Center in the United States. In 2010, he established the Department of Pancreatic Surgery at FUSCC. Under his leadership, the department has grown into a world-class clinical and research center, leading Shanghai in the volume of pancreatic malignancy surgeries for eight consecutive years.
Dedicated to translational research, Dr. Yu focuses on improving the safety and efficacy of pancreatic cancer surgeries. He has innovated surgical techniques and comprehensive treatment strategies that have significantly prolonged patient survival. As a leading figure in his field, he has been invited to speak at major international conferences such as the International Association of Pancreatology (IAP) and the Japan Society of Clinical Oncology (JSCO).
Book an online consultation with Dr. Xianjun Yu
Areas of Expertise
-
Radical Surgery for Pancreatic Tumors: Specializes in complex resections for pancreatic ductal adenocarcinoma and other malignancies.
-
Minimally Invasive Surgery: Expert in robotic and laparoscopic pancreatic surgery.
-
Pancreatic Neuroendocrine Tumors (pNETs): Comprehensive diagnosis and surgical management.
-
Hepato-biliary Surgery: Surgical treatment of liver and gallbladder tumors.
-
Comprehensive Treatment: Individualized multidisciplinary treatment (MDT) plans aimed at prolonging survival for advanced pancreatic cancer patients.
Clinical Highlights
-
Over 21,800 patients treated
-
99% treatment satisfaction rate
-
99% patient satisfaction with service attitude
Work Experience
-
President, Fudan University Shanghai Cancer Center, Shanghai, China (Current).
-
Director (Chair), Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center (2010 – Current).
-
Director, Pancreatic Cancer Institute, Fudan University / Shanghai Pancreatic Cancer Institute.
-
Postdoctoral Fellow / Visiting Scholar, MD Anderson Cancer Center & Baylor College of Medicine, USA.
-
Professor & Chief Physician, Fudan University Shanghai Cancer Center.
Social Appointments
-
Chairman, Committee of Pancreatic Cancer, Chinese Anti-Cancer Association (CACA).
-
Head, Chinese Study Group for Pancreatic Cancer (CSPAC).
-
Fellow, American College of Surgeons (FACS).
-
Standing Committee Member, Pancreatic Disease Committee, Chinese Medical Doctor Association.
-
Committee Member, Pancreatic Surgery Group, Surgery Branch of the Chinese Medical Association.
Honors & Awards
-
Distinguished Young Scholar, National Science Fund for Distinguished Young Scholars.
-
Chang Jiang Scholar, Ministry of Education of China.
-
National May 1st Labor Medal.
-
Leading Talent of Shanghai.
-
Shanghai Technology Elite.
-
Recipient, Special Government Allowance of the State Council.
Research Achievements
-
High-Impact Publications: Published over 250 SCI papers in prestigious journals including Journal of Clinical Oncology, Gut, Annals of Surgery, Cell Research, and Clinical Cancer Research.
-
Surgical Innovations: Invented a new pancreaticojejunostomy technique to reduce postoperative pancreatic fistula rates, which has been cited in international clinical guidelines.
-
Clinical Strategy: Proposed individualized chemotherapy strategies based on stromal proportion in pancreatic cancer.
-
Patents: Holds 5 national patents for practical medical models and surgical instruments.
-
Funding: Principal investigator for multiple national-level projects, including key projects for the National Natural Science Foundation of China.
*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.